Member Info for Laura2022

The new permanent role was explained in Peters 3 part triangle diagram.. namely to have someone permanent to oversee the increased client work

As you say peter was excited about bio stats but also the dosing tool potential

Only own about 5% between them ..maybe why one of them frantically purchased 4mln last week

The other holders are below, òn the circular it still doesn't say anyone is supporting this motion APART from the directors

ShareholderPercentage HeldAndrew Scott (and related parties)*25.2%Credit Suisse7.9%Hargreaves Lansdown Asset Management7.1%Canaccord Genuity Wealth Management6.9%Interactive Investor5.6%Schroder Investment Management4.1%Jarvis Investment Management3.9%Adara Ventures SICAR3.4%Herald Investment Management

Particularly the 20-35min and the final 10 mins Q and a

Evening Jack

Everything today was a buy ...particularly the 1.3p and 1.34p ones

Can sell 800,000 at 0.59p but can buy 100,000 at 0.6p

More buys today than for weeks

People scoffed when i mentioned CPX 0.07p

Rose 400% in total

LOOP is next as there is a buyer trying to scupper mgmt plans to de list

Opposite for me

Can't buy £1k

Yes King

Also an outside we could maybe beat the expectations (Pyc said said would be met last week)

The Company's pipeline of potential new business now stands at over £1.5m (not risk weighted and excluding Biostatistics), counting only opportunities where a specific project has been discussed with a client. The Company is working hard to both convert opportunities that have progressed to proposal stage and also to refill the funnel with earlier stage opportunitie

Rise

That's me all out

Great run from 07p

Merck it sounds like

Looking forward to beating those £1mln revenues

The project involves Pharmacokinetic-Pharmacodynamic (PKPD) modelling in the field of DNA damage/ repair field and will help inform clinical dose and scheduling decisions. The value of the project is £178k and it is anticipated that it will be completed over the course of the next six months.

 

Dr Peter Sargent, CEO, commented: "We are very pleased that we've been awarded this substantial project and we very much look forward to working with the client team on this exciting project".

Should be another good day

Buying at 0.07p was risky but worth it !

RQIH could do big jump

Net assets confirmed at 80 cents despite just 6p share price now the business have been de leveraged after $450mln asseet sale approved by EU

Volume on Friday after 3pm was highest in months

I will be buying on Monday

What negative comment did I post ?

None !

Adjusted for closing of the Sale and subsequent de-leveraging of R&Q assuming Available Net Cash Proceeds of $170 million (at the lower end of the expected range), R&Q's current estimated pro-forma financial position as at 30 June 2023 would be as follows:

Assets

$2.0 billion

Debt

$203 million

Shareholders' Equity

$356 million

Debt to Capital Ratio

36%

Group Solvency Ratio

>200%

Net Asset Value Per Common Share

80 cents

Thankyou TallPaul

I suggested that someone would want to aquire CPX and this TR1 from someone connected to ITM seems to confirm this

All people had to do was email the company as I did yesterday

RQIH £23ml market cap and now announced $430mln buy out of assets ...minus the debt it owes leaves a huge upside

See RQIH board

The European Commission has approved private equity firm Onex Corporation’s proposed $465mn acquisition of R&Q’s profitable program fronting platform Accredited